{"id":"mcc-tt","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MCC-TT combines meningococcal polysaccharide antigens with tetanus toxoid as a carrier protein to enhance immunogenicity and promote T-cell mediated immunity. This conjugate vaccine approach aims to provide protection against meningococcal disease while simultaneously boosting or maintaining tetanus immunity in a single formulation.","oneSentence":"MCC-TT is a therapeutic vaccine designed to stimulate immune responses against meningococcal and tetanus pathogens through conjugate technology.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:23.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease and tetanus"}]},"trialDetails":[{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01777308","phase":"PHASE3","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-05-03","conditions":"Infections, Meningococcal","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NEISVAC-C®"],"phase":"phase_3","status":"active","brandName":"MCC-TT","genericName":"MCC-TT","companyName":"MCM Vaccines B.V.","companyId":"mcm-vaccines-b-v","modality":"Biologic","firstApprovalDate":"","aiSummary":"MCC-TT is a therapeutic vaccine designed to stimulate immune responses against meningococcal and tetanus pathogens through conjugate technology. Used for Prevention of meningococcal disease and tetanus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}